Answers are grounded in this paper and cite their sources.
Regulatory genes are often hypermethylated at their promoter 5' regions and silenced in cancer. Epigenetic therapy with DNA methylation inhibitors have been shown to result in the demethylation and reactivation of these genes. Zebularine is a recently discovered mechanism-based inhibitor of DNA methylation, and has received much attention for its potential in clinical use. Further studies exploring the effectiveness of zebularine in a variety of settings could allow the development of novel therapies for cancer.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: